TAK-019

BIOLOGICAL2 trials

Sponsors

Takeda

Conditions

Coronavirus Disease (COVID-19)Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Phase 1

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

CompletedNCT04712110

TakedaPrevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Start: 2021-02-12End: 2022-03-28Updated: 2023-06-06

Phase 3

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

CompletedNCT05299359

TakedaCoronavirus Disease (COVID-19)

Start: 2022-04-15End: 2023-10-18Updated: 2024-10-21

Related Papers

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial.

2025-08-05

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.

2023-05-085 citations

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

Vaccine2022-04-2920 citations